These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 19375979

  • 1. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.
    Borget MY, Diallo K, Adje-Toure C, Chorba T, Nkengasong JN.
    J Clin Virol; 2009 May; 45(1):72-5. PubMed ID: 19375979
    [Abstract] [Full Text] [Related]

  • 2. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA, Cheingsong R, Garcìa-Lerma JG, Eholié S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, Nolan M, Chorba T, Heneine W, Nkengasong JN.
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire.
    Bilé EC, Adjé-Touré C, Borget MY, Kalou M, Diomande F, Chorba T, Nkengasong JN.
    J Clin Virol; 2005 Jan; 32(1):60-6. PubMed ID: 15572008
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME.
    Medicina (B Aires); 1998 Jan; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract] [Full Text] [Related]

  • 7. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.
    AIDS; 2008 Jul 11; 22(11):1305-12. PubMed ID: 18580610
    [Abstract] [Full Text] [Related]

  • 8. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy.
    Clark NM, Dieng Sarr A, Sankalé JL, Kanki PJ, Kazanjian P, Winfield R, Markovitz DM.
    AIDS; 1998 Dec 24; 12(18):2506-7. PubMed ID: 9875594
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J, Brooks JT, Baker R, Hoffman M, Moorman A, Novak R, HOPS Investigators.
    Antivir Ther; 2007 Dec 24; 12(6):957-62. PubMed ID: 17926650
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.
    Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.
    Scand J Immunol; 2008 Dec 24; 68(6):652-60. PubMed ID: 19055701
    [Abstract] [Full Text] [Related]

  • 15. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S, Garrido C, Youngpairoj AS, McNulty A, Zahonero N, Corral A, Heneine W, de Mendoza C, García-Lerma JG.
    AIDS; 2007 Nov 30; 21(18):2503-11. PubMed ID: 18025887
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG.
    AIDS; 2009 Jul 31; 23(12):1605-8. PubMed ID: 19487903
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.
    AIDS; 2008 Nov 12; 22(17):2371-80. PubMed ID: 18981777
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 12; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.